Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359549 | 1.00 | ADORA1 (0.51) | ADORA1ADORA2AADORA2BP2RX3 | |
| SCHEMBL31359559 | 0.91 | ADORA2A (0.49) | ADORA1ADORA2AADORA2BP2RX3 | |
| SCHEMBL31359548 | 0.91 | ADORA2A (0.49) | ADORA1ADORA2AADORA2BP2RX3 | |
| SCHEMBL31359573 | 0.91 | ADORA2A (0.49) | ADORA1ADORA2AADORA2BP2RX3 | |
| SCHEMBL8619744 | 0.86 | ADORA2A (0.60) | ADORA2AADORA2B | |
| SCHEMBL8619750 | 0.86 | ADORA2A (0.60) | ADORA2AADORA2B | |
| SCHEMBL31359572 | 0.84 | ADORA1 (0.51) | ADORA1ADORA2AADORA2BP2RX3 | |
| SCHEMBL23854438 | 0.83 | ADORA1 (0.60) | ADORA1ADORA2AADORA2B | |
| SCHEMBL29832776 | 0.83 | ADORA1 (0.60) | ADORA1ADORA2AADORA2B | |
| SCHEMBL6112601 | 0.80 | ADORA2A (0.73) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ADAR, ADA, NUDT1 | ADORA1 107/4885ADORA2A 36/4885ADORA2B 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.